866-997-4948(US-Canada Toll Free)

Invega Sustenna Analysis and Forecasts from 2009 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 30 Pages


GlobalDatas pharmaceuticals report, Invega Sustenna Analysis and Forecasts from 2009 to 2020 provides Invega Sustenna sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information onSchizophrenia market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Invega Sustenna including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Invega Sustenna including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Invega Sustenna in each of the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Schizophrenia 4
2.2 Symptoms 4
2.3 Schizophrenia Market 4
2.4 Epidemiology 4
2.5 Etiology 5
2.5.1 Genetic Factors 5
2.5.2 Environmental Factors 5
2.5.3 Abnormal Brain Structure 6
2.6 GlobalData Report Guidance 6

3 Schizophrenia: Market Characterization 7
3.1 Schizophrenia Market 7
3.2 Schizophrenia Market Forecasts and CAGR 7
3.3 Drivers of Schizophrenia Therapeutics Market 8
3.3.1 Patent Expiry of Leading Marketed Drugs 8
3.3.2 Increasing Patient Pool 8
3.3.3 High Prescription Rates 8
3.3.4 Low Patient Compliance Rate 8
3.3.5 High Unmet Need 8

4 Classification of Schizophrenia 9
4.1 Age of Onset of Schizophrenia 9
4.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
4.1.2 Adult Schizophrenia 10
4.2 Associated Symptoms 10
4.2.1 Paranoid Schizophrenia 10
4.2.2 Disorganized Schizophrenia 10
4.2.3 Catatonic Schizophrenia 10
4.2.4 Residual Schizophrenia 10
4.2.5 Undifferentiated Disorder 10

5 Treatment for Schizophrenia 11
5.1 Crisis Resolution Teams (CRT) 11
5.2 Voluntary and Compulsory Detention 11
5.3 Antipsychotics 11
5.3.1 Typical Antipsychotics 11
5.3.2 Atypical Antipsychotics 12
5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis 12

6 Invega Sustenna 13
6.1 Introduction 13
6.2 Mechanism of Action 13
6.3 Clinical Studies 13
6.4 Approval History of Invega Sustenna 14
6.5 Factors Affecting Sales of Invega Sustenna 14
6.5.1 High compliance 14
6.5.2 High competition 14
6.5.3 Low safety profile 14
6.5.4 Lack of presence in Japan 14
6.6 Drug Evaluation 14
6.6.1 Drug Risk Benefit Score 14
6.6.2 Intensity of Competition 15
6.7 Sales Estimates 17
6.7.1 Target Patient Pool of Invega Sustenna 17
6.7.2 Dosing 17
6.7.3 Market Penetration 17
6.7.4 Annual Cost of Therapy 18
6.7.5 Sales Estimates of Invega Sustenna 19

7 Schizophrenia Market: Appendix 27
7.1 Market Definitions 27
7.2 Abbreviations 27
7.3 Research Methodology 27
7.4 Drug Sales Estimates Model 29
7.5 Contact Us 29
7.6 Disclaimer 30
7.7 Sources 30

List of Table


Table 1: Invega Sustenna, Phase III Clinical Trials Results 13
Table 2: Invega Sustenna, Approval History 14
Table 3: Drug Risk Benefit Score of Invega Sustenna 15
Table 4: Competitors of Invega Sustenna 16
Table 5: Invega Sustenna, Annual Treatment Costs for Schizophrenia ($), 2011 18
Table 6: Invega Sustenna, Schizophrenia, Global, Sales Estimates ($m), 20092020 19
Table 7: Invega Sustenna, Schizophrenia, The US, Sales Estimates ($m), 20092020 20
Table 8: Invega Sustenna, Schizophrenia, The UK, Sales Forecasts ($m), 20112020 21
Table 9: Invega Sustenna, Schizophrenia, France, Sales Forecasts ($m), 20112020 22
Table 10: Invega Sustenna, Schizophrenia, Germany, Sales Forecasts ($m), 20112020 23
Table 11: Invega Sustenna, Schizophrenia, Italy, Sales Forecasts ($m), 20112020 24
Table 12: Invega Sustenna, Schizophrenia, Spain, Sales Forecasts ($m), 20112020 25

List of Chart


Figure 1: Risk of Developing Schizophrenia 5
Figure 2: Environmental Factors in the Development of Schizophrenia 6
Figure 3: Schizophrenia, Global, Market Size Forecasts ($bn), 20102020 7
Figure 4: Classification of Schizophrenia based on the Age of Disease Onset 9
Figure 5: Reduction in PANSS Scores for Atypical Antipsychotics 16
Figure 6: Drug Model Diagram of Invega Sustenna 17
Figure 7: Invega Sustenna, Schizophrenia, Global, Sales Estimates ($m), 20092020 19
Figure 8: Invega Sustenna, Schizophrenia, The US, Sales Estimates ($m), 20092020 20
Figure 9: Invega Sustenna, Schizophrenia, The UK, Sales Forecasts ($m), 20112020 21
Figure 10: Invega Sustenna, Schizophrenia, France, Sales Forecasts ($m), 20112020 22
Figure 11: Invega Sustenna, Schizophrenia, Germany, Sales Forecasts ($m), 20112020 23
Figure 12: Invega Sustenna, Schizophrenia, Italy, Sales Forecasts ($m), 20112020 24
Figure 13: Invega Sustenna, Schizophrenia, Spain, Sales Forecasts ($m), 20112020 25
Figure 14: Invega Sustenna, Schizophrenia, Global, Sales Distribution in Major Countries (%), 2020 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *